Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1

Cell Death and Disease

Volumn 2, Issue 5, 2011, Pages

  Ahmed, A ^a   Yang, J ^a,c   Maya Mendoza, A ^b   Jackson, D A ^b   Ashcroft, M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

CHK 1; DNA damage; HIF 1 ; Hypoxia; P53

Indexed keywords

2,5 BIS(5 HYDROXYMETHYL 2 THIENYL)FURAN; ANTINEOPLASTIC AGENT; ATM PROTEIN; CASPASE 3; CHECKPOINT KINASE 1; CHECKPOINT KINASE RAD3; HISTONE H2AX; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NSC 652287; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; FURAN DERIVATIVE; H2AFX PROTEIN, HUMAN; HIF1A PROTEIN, HUMAN; HISTONE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME REACTIVATION; FLUORESCENCE ACTIVATED CELL SORTING; GENOTOXICITY; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANOXIA; ATAXIA TELANGIECTASIA; BIOSYNTHESIS; BREAST TUMOR; COLORECTAL TUMOR; DNA REPLICATION; DNA REPLICATION ORIGIN; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; OSTEOSARCOMA; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ATAXIA TELANGIECTASIA;

ANOXIA; APOPTOSIS; ATAXIA TELANGIECTASIA; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA DAMAGE; DNA REPLICATION; FEMALE; FURANS; GENE KNOCKDOWN TECHNIQUES; HISTONES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; OSTEOSARCOMA; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; REPLICATION ORIGIN; S PHASE; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79959929894     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2011.42     Document Type: Article

References (39)

1. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010; 40: 294-309.
2. Poon E, Harris AL, Ashcroft M. Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert Rev Mol Med 2009; 11: e26.
3. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW et al. Hypoxiamediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379: 88-91. (Pubitemid 26008141)
4. Stempien-Otero A, Karsan A, Cornejo CJ, Xiang H, Eunson T, Morrison RS et al. Mechanisms of hypoxia-induced endothelial cell death. Role of p53 in apoptosis. J Biol Chem 1999; 274: 8039-8045.
5. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000; 14: 34-44. (Pubitemid 30051577)
6. Kaluzova M, Kaluz S, Lerman MI, Stanbridge EJ. DNA damage is a prerequisite for p53- mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. Mol Cell Biol 2004; 24: 5757-5766. (Pubitemid 38787961)
7. Salnikow K, Costa M, Figg WD, Blagosklonny MV. Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer. Cancer Res 2000; 60: 5630-5634.
8. Foster BA, Coffey HA, Morin MJ, Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 1999; 286: 2507-2510.
9. Bykov VJ, Wiman KG. Novel cancer therapy by reactivation of the p53 apoptosis pathway. Ann Med 2003; 35: 458-465. (Pubitemid 37421557)
10. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848. (Pubitemid 38174664)
11. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006; 103: 1888-1893. (Pubitemid 43228788)
12. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M et al. 2004 Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10: 1321-1328. (Pubitemid 40022713)
13. Rivera MI, Stinson SF, Vistica DT, Jorden JL, Kenney S, Sausville EA. Selective toxicity of the tricyclic tiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism. Biochem Pharmacol 1999; 57: 1283-1295. (Pubitemid 29185150)
14. Nieves-Neira W, Rivera MI, Kohlhagen G, Hursey ML, Pourquier P, Sausville EA et al. DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells. Mol Pharmacol 1999; 56: 478-484. (Pubitemid 29406874)
15. Yang J, Ahmed A, Poon E, Perusinghe N, de Haven Brandon A, Box G et al. Smallmolecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol Cell Biol 2009; 29: 2243-2253.
16. Enge M, Bao W, Hedstrom E, Jackson SP, Moumen A, Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009; 15: 171-183.
17. Yang J, Ahmed A, Ashcroft M. Activation of a unique p53-dependent DNA damage response. Cell Cycle 2009; 8: 1630-1632.
18. Kao J, Milano MT, Javaheri A, Garofalo MC, Chmura SJ, Weichselbaum RR et al. gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr Cancer Drug Targets 2006; 6: 197-205. (Pubitemid 43764740)
19. Ashcroft M, Kubbutat MH, Vousden KH. Regulation of p53 function and stability by phosphorylation. Mol Cell Biol 1999; 19: 1751-1758. (Pubitemid 29098233)
20. Bradbury JM, Jackson SP. ATM and ATR. Curr Biol 2003; 13: R468.
21. Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA 1999; 96: 13777-13782.
22. Marti TM, Hefner E, Feeney L, Natale V, Cleaver JE. H2AX phosphorylation within the G1 phase after UV irradiation depends on nucleotide excision repair and not DNA doublestrand breaks. Proc Natl Acad Sci USA 2006; 103: 9891-9896. (Pubitemid 43993593)
23. Merrick CJ, Jackson D, Diffley JF. Visualization of altered replication dynamics after DNA damage in human cells. J Biol Chem 2004; 279: 20067-20075. (Pubitemid 38623451)
24. Jackson DA, Pombo A. Replicon clusters are stable units of chromosome structure: evidence that nuclear organization contributes to the efficient activation and propagation of S phase in human cells. J Cell Biol 1998; 140: 1285-1295. (Pubitemid 28152979)
25. Maya-Mendoza A, Petermann E, Gillespie DA, Caldecott KW, Jackson DA. Chk1 regulates the density of active replication origins during the vertebrate S phase. EMBO J 2007; 26: 2719-2731. (Pubitemid 46884282)
26. Niida H, Murata K, Shimada M, Ogawa K, Ohta K, Suzuki K et al. Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo. Embo J 2010; 29: 3558-3570.
27. Paulsen RD, Cimprich KA. The ATR pathway: fine-tuning the fork. DNA Repair (Amst) 2007; 6: 953-966. (Pubitemid 46880476)
28. Robinson HM, Jones R, Walker M, Zachos G, Brown R, Cassidy J et al. Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene 2006; 25: 5359-5369. (Pubitemid 44330279)
29. Petermann E, Maya-Mendoza A, Zachos G, Gillespie DA, Jackson DA, Caldecott KW. Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase. Mol Cell Biol 2006; 26: 3319-3326.
30. Petermann E, Woodcock M, Helleday T. Chk1 promotes replication fork progression by controlling replication initiation. Proc Natl Acad Sci USA 2010; 107: 16090-16095.
31. Collis SJ, Barber LJ, Clark AJ, Martin JS, Ward JD, Boulton SJ. HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability. Nat Cell Biol 2007; 9: 391-401. (Pubitemid 46511072)
32. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2009; 29: 625-634.
33. Shimura T, Toyoshima M, Adiga SK, Kunoh T, Nagai H, Shimizu N et al. Suppression of replication fork progression in low-dose-specific p53-dependent S-phase DNA damage checkpoint. Oncogene 2006; 25: 5921-5932. (Pubitemid 44477286)
34. Agarwal ML, Agarwal A, Taylor WR, Chernova O, Sharma Y, Stark GR. A p53-dependent S-phase checkpoint helps to protect cells from DNA damage in response to starvation for pyrimidine nucleotides. Proc Natl Acad Sci USA 1998; 95: 14775-14780. (Pubitemid 29003706)
35. Vaziri C, Saxena S, Jeon Y, Lee C, Murata K, Machida Y et al. A p53-dependent checkpoint pathway prevents rereplication. Mol Cell 2003; 11: 997-1008. (Pubitemid 36566321)
36. Sorensen CS, Hansen LT, Dziegielewski J, Syljuasen RG, Lundin C, Bartek J et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005; 7: 195-201. (Pubitemid 40268135)
37. Sengupta S, Linke SP, Pedeux R, Yang Q, Farnsworth J, Garfield SH et al. BLM helicasedependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination. EMBO J 2003; 22: 1210-1222. (Pubitemid 36313604)
38. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282: 1497-1501. (Pubitemid 28538613)
39. Carroll VA, Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 2006; 66: 6264-6270.